Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Myrexis
(OTCEM:MYRX)
Intraday
$0.0105
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$0.0105
0
[0.00%]
At close: Apr 15
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Myrexis Stock (OTC:MYRX)
Myrexis Stock (OTC: MYRX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, January 23, 2013
UPDATE: Myrexis Names Jonathan Couchman as President, CEO
Benzinga
-
Jan 23, 2013, 9:06AM
Myrexis to Abandon Proposed Plan of Dissolution, Will Continue to Evaluate Alternatives; Board Approves Special Cash Distribution of $2.86/Share
Benzinga
-
Jan 23, 2013, 9:06AM
Monday, November 12, 2012
Benzinga's Microcap Movers for Monday November 12, 2012
Benzinga
-
Nov 12, 2012, 5:35PM
Friday, November 09, 2012
Myrexis Resumes Trading
Benzinga
-
Nov 9, 2012, 4:36PM
Myrexis Announces Board Approval to Liquidate Assets
Benzinga
-
Nov 9, 2012, 4:04PM
Myrexis Halted, Pending News
Benzinga
-
Nov 9, 2012, 4:02PM
Myrexis Trading Halted News Pending
Benzinga
-
Nov 9, 2012, 4:00PM
Thursday, September 13, 2012
Myrexis Suspends Development Activity on All Programs
Benzinga
-
Sep 13, 2012, 4:22PM
Wednesday, August 15, 2012
Myrexis CEO Brewer passes away
Benzinga
-
Aug 15, 2012, 12:38PM
Friday, May 11, 2012
Myrexis Appoints New Executive Management Team in Alignment With Strategic Initiatives
Benzinga
-
May 11, 2012, 8:00AM
Friday, March 30, 2012
Myrexis Adopts Tax Benefits Preservation Rights Plan to Protect Use of Net Operating Losses Replacing Existing Shareholder Rights Plan
Benzinga
-
Mar 30, 2012, 8:31AM
Wednesday, February 15, 2012
UPDATE: Myrexis Suspends All Preclinical And Clinical Programs
Benzinga
-
Feb 15, 2012, 12:18PM
Myrexis Retains Investment Bank to Explore Strategic Alternatives
Benzinga
-
Feb 15, 2012, 12:17PM
Trading Halted in Myrexis, News Pending
Benzinga
-
Feb 15, 2012, 11:59AM
Wednesday, November 30, 2011
p-Value Capital Management to Withhold Votes From Directors of Myrexis, Inc. at Upcoming Election
Benzinga
-
Nov 30, 2011, 4:02PM
Friday, November 18, 2011
Myrexis Announces Corporate Reorganization to Focus on Development Objectives
Benzinga
-
Nov 18, 2011, 11:46AM
Thursday, October 20, 2011
Myrexis Appoints Jason M. Aryeh to its Board of Directors
Benzinga
-
Oct 20, 2011, 4:38PM
Friday, September 09, 2011
Rodman & Renshaw Reiterates Myrexis Market Outperform, $6 PT
Benzinga
-
Sep 9, 2011, 9:52AM
Thursday, September 08, 2011
Myrexis Resumes Trading
Benzinga
-
Sep 8, 2011, 4:32PM
PREVIEW: Myrexis to Resume Trading at 4:30pm
Benzinga
-
Sep 8, 2011, 4:05PM
Myrexis Appoints Robert Lollini CEO
Benzinga
-
Sep 8, 2011, 4:04PM
Myrexis Board of Directors Appoints Robert Lollini CEO
Benzinga
-
Sep 8, 2011, 4:02PM
Earnings Scheduled For September 8
Benzinga
-
Sep 8, 2011, 3:59AM
Tuesday, August 02, 2011
Stocks to Watch for Tuesday 8/02/2011: Fresh 52-Week Highs and Lows
Benzinga
-
Aug 2, 2011, 4:20AM
Wednesday, July 27, 2011
Rodman & Renshaw Intiatiate Coverage of Myrexis at Market Outperform with a PT of $6
Benzinga
-
Jul 27, 2011, 8:07AM
Rodman & Renshaw Initiates Coverage of Myrexis with Market Outperform and PT of $6
Benzinga
-
Jul 27, 2011, 3:06AM
Tuesday, July 26, 2011
Hearing Myrexis Initiated at Rodman With $6 PT
Benzinga
-
Jul 26, 2011, 5:02PM
Friday, July 22, 2011
Myrexis CEO Resigns
Benzinga
-
Jul 22, 2011, 8:30AM
Monday, June 06, 2011
Myrexis Reports Azixa Phase 2 Study Results at 2011 American Society of Clinical Oncology Annual Meeting
Benzinga
-
Jun 6, 2011, 8:03AM
Piper Jaffray Maintains Neutral on Myrexis
Benzinga
-
Jun 6, 2011, 7:29AM
Thursday, May 19, 2011
Piper Jaffray Maintains Neutral Rating On Myrexis
Benzinga
-
May 19, 2011, 8:01AM
Wednesday, April 06, 2011
Myrexis Trades 7% Higher After Drug Data Announcment (MYRX)
Benzinga
-
Apr 6, 2011, 9:31AM
Tuesday, March 29, 2011
Myrexis Reorganizes to Align Resources With Current Pipeline; Reduces 41% of Workforce
Benzinga
-
Mar 29, 2011, 12:15PM
Trading Halted: Myrexis, News Pending
Benzinga
-
Mar 29, 2011, 11:58AM
Wednesday, December 22, 2010
Myrexis Initiates Comparative-Arm Phase 2 Study of Azixa
Benzinga
-
Dec 22, 2010, 4:21PM
Monday, November 29, 2010
Insiders Trading MYRX, LKQX and HOTT
Benzinga
-
Nov 29, 2010, 9:29AM
Thursday, September 09, 2010
Earnings Scheduled For September 9 (SWHC, NSM, PNY, CHP, VALU, ULCM, DSGX, IRET, KFY, MVC, MYRX, OXBT, PNY)
Benzinga
-
Sep 9, 2010, 6:00AM
Monday, April 12, 2010
Market Roundup (C, AAPL, HPQ, DELL, MSFT, NOK, GOOG, CAL, UAUA, LCC, ADBE, JAV, MYRX, HSP)
Benzinga
-
Apr 12, 2010, 3:40PM